Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis and Medicis Pharmaceutical, a subsidiary of Valeant Pharmaceuticals, have resolved patent litigations related to Actavis' abbreviated new drug application (ANDA) for clindamycin and tretinoin gel and imiquimod cream.
Subscribe to our email newsletter
Clindamycin and Tretinoin Gel is generic version of Ziana and Imiquimod Cream is a generic version of Zyclara.
Under the terms of the agreement Actavis may launch its generic version of Ziana in July 2016, or earlier under certain circumstances and generic version of Zyclara on 1 January 2019, or earlier under certain circumstances.
A share of the economics from the generic products sold under the agreements will be given to Valeant.
Lincosamide antibiotic and retinoid combination product Ziana is indicated for the topical treatment of acne vulgaris in patients aged 12 years and more.
Prescription medicine Zyclara is indicated for actinic keratosis on the full face or balding scalp in adults with a normal immune function.